Regeneron Pharmaceuticals reported that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to its supplemental biologics license application (sBLA) for the addition of extended dosing intervals (up to every 24 weeks) for aflibercept 8 mg (Eylea HD) across all approved indications.

The FDA did not agree with Regeneron’s proposal to add additional extended dosing intervals (greater than every 16 weeks, which is the maximum dosing interval currently indicated in the label), the company said in a press release. The CRL did not identify any issues with the safety or efficacy of Eylea HD in its approved indications and dosing regimens, the company said.

Regeneron said it is evaluating the FDA’s decision and will determine a path forward in due course.

Eylea HD is approved with dosing intervals from every 8 to 16 weeks for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), and every 8 to 12 weeks for patients with diabetic retinopathy (DR), following 3 initial monthly doses, the company said. Last week, Regeneron reported that it had received priority review status for its sBLA for aflibercept 8 mg for the treatment of macular edema secondary to retinal vein occlusion (RVO). RP